Investors
Events & Presentations
Financial & Filings
Stock Information
Investor FAQs
Contact Us
Newsroom
Careers
Job Openings
Areas of Focus
Cardiometabolic
Severe Hypertriglyceridemia
Dyslipidemia
Cardiovascular Disease
Obesity
Pulmonary
Inflammatory Pulmonary Diseases
Idiopathic Pulmonary Fibrosis
Our Medicines
Pipeline
Science & Innovation
Partnerships
Publications
Clinical Trials
Patients & Caregivers
What is RNAi?
Patient Centricity & Advocacy
Patient Stories
FCS Patient Insights
Patient Education
About
Leadership Team
Corporate Governance
Investors
Events & Presentations
Financial & Filings
Stock Information
Investor FAQs
Contact Us
Newsroom
Careers
Job Openings
Latest News and Events
Home
/
Newsroom
Now Approved
FDA Approval of Plozasiran to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Filter by
Year Published
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Selections
Clear Filters
January 8, 2011
Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals
Read More
Prev
1
...
56
57
58
Continue to Site
Cancel
